Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19)




renin-angiotensin system inhibitors, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, direct renin inhibitor, COVID-19, BIRCOV trial


Background. The question of the possible effect of the inhibitors of the renin-angiotensin system (iRAS) on hypertensive subjects who fell ill with COVID-19 has been discussed in the literature. SARS-CoV-2 is well-known to use an angiotensin-converting enzyme 2 receptors facilitating virus entry into host cells. There are three possible mechanisms of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) effect in COVID-19 in clinical practice: with worsening, neutral, or helpful function. Considering the different mechanisms of blood pressure reduction by iRAS, one can expect differences in people with COVID-19 receiving these drugs. The purpose of the BIRCOV study is to pinpoint possible clinical and laboratory differences in hypertensive people who received iRAS and suffered from coronavirus infection. Materials and methods. Patient-Oriented Evidence that Matters (POEM) intervention was designed as an open prospective randomized two medical centers trial in subjects suffering from COVID-19 who have been receiving iRAS, either ACEi, ARB, or direct renin inhibitor (DRi) as basic antihypertensive therapy. One hundred and twenty people with stage 1–2 hypertension have been screened, 108 subjects were enrolled in the BIRCOV study. COVID-19 was confirmed by a PCR test; the disease follow-up was divided into 2 periods: up to 12 weeks and up to 24 weeks. The primary outcome measure was as follows: blood pressure (BP) was known one week before COVID-19 onset and was measured during the disease on weeks 2, 4, 12, 24. The secondary outcome measures were clinical features. Subanalysis in patients with chronic kidney disease (CKD) was performed. Results. All patients were randomized into 3 groups who received: ACEi — 42 (39 %), ARB — 35 (32 %), or DRi — 31 (29 %). The BIRCOV trial documented the trend of BP lowering in the first two weeks of the COVID-19 disease with its gradual return to baseline values up to the 12th week. Twenty-three (21 %) patients have withdrawn medicine for up to 2 weeks due to severe hypotension. However, the BP values after COVID-19 in most subjects remained lower than the baseline ones for 4 weeks. The use of ACE inhibitors significantly increased the risk of withdrawal compared to DRi (RR 1.648; 95% CI 0.772–3.519; NNT 7.0) and ARB (RR 13.023; 95% CI 1.815–93.426; NNT 2.9) due to COVID-19. The synchronous decline of estimated glomerular filtration rate (eGFR) and systolic BP was more pronounced in CKD patients. The greatest decrease in eGFR was noted in people who have been taking ACEi. The drop in eGFR ranged from 23 % in CKD stage 1 to 45 % in CKD stage 4. Two people required short-term dialysis. The analysis of secondary outcome points demonstrated that in 23 % of people without preceding albuminuria it developed in the A2 range. During 12 weeks of observation, 81 % of patients had spontaneous albuminuria reduction. Post-COVID-19 (above 12 weeks) albuminuria remained in 19 % of patients, 90 % of them had a history of CKD. Patients with preceding CKD had an increase in albuminuria in 78 % of cases, and its return to the baseline was observed only in 24 % of patients by the 12th week and in 49 % of individuals in 24 weeks. Conclusions. People with stage 1–2 hypertension who are receiving chronic iRAS and suffer from COVID-19 may develop hypotension with ACE inhibitors. COVID-19 leads to transient albuminuria and decreased glomerular filtration rate, which is especially dangerous for people with CKD.


Download data is not yet available.


European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). COVID-19: news and information. Available from:

Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi:10.1056/NEJMoa2008975.

Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-1326. doi:10.1161/CIRCRESAHA.121.318902.

Bojkova D, Klann K, Koch B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020 Jul;583(7816):469-472. doi:10.1038/s41586-020-2332-7.

Davidson AD, Williamson MK, Lewis S, et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome Med. 2020 Jul 28;12(1):68. doi:10.1186/s13073-020-00763-0.

Nephrology Journal Club (NephJC). ACE2 and hypertension. Available from: Accessed: October 4, 2020.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020 Jun 18;382(25):e102. doi:10.1056/NEJMoa2007621.

Mourad JJ, Levy BI. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat Rev Cardiol. 2020 May;17(5):313. doi:10.1038/s41569-020-0368-x.

Evidence-Based Practice and Information Mastery: POEMs and DOEs. Available from:

Ivanova MD, Gozhenko AI, Crestanello T, Ivanov DD. Early Coaching to Increase Water Intake in CKD. Ann Nutr Metab. 2020;76(Suppl 1):69-70. doi:10.1159/000515276.

GIGA Online Calculators. Available from:

Kidney Failure Risk Equation (4 Variable): Calculator. Available from:

Nephrology Journal Club (NephJC). COVID-19. Available from:

Aronson JK, Ferner RE. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19. Available from: Accessed: March 31, 2020.

Cohen JB, South AM, Shaltout HA, Sinclair MR, Sparks MA. Renin-angiotensin system blockade in the COVID-19 pandemic. Clin Kidney J. 2021 Feb 2;14(Suppl 1):i48-i59. doi:10.1093/ckj/sfab026.

Najmeddin F, Solhjoo M, Ashraf H, et al. Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial. Am J Hypertens. 2021 Jul 15:hpab111. doi:10.1093/ajh/hpab111.

ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94. doi:10.1093/ndt/gfaa314.

Chung EY, Palmer SC, Natale P, et al. Incidence and Outcomes of COVID-19 in People with CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2021 Aug 5:S0272-6386(21)00771-X. doi:10.1053/j.ajkd.2021.07.003.

Jia N, Zhang G, Sun X, et al. Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis. J Clin Hypertens (Greenwich). 2021 Jul 28. doi:10.1111/jch.14329.

Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021 Aug 9;11(1):16144. doi:10.1038/s41598-021-95565-8.




How to Cite

Ivanov, D., Ivanova, M., & Crestanello, T. (2022). Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19). KIDNEYS, 10(3), 143–149.



Original Articles

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>